Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Breast cancer risks associated with missense variants in breast cancer susceptibility genes

Research output: Contribution to journalJournal articlepeer-review

  1. Introduction and transmission of SARS-CoV-2 lineage B.1.1.7, Alpha variant, in Denmark

    Research output: Contribution to journalJournal articlepeer-review

  2. The global dissemination of hospital clones of Enterococcus faecium

    Research output: Contribution to journalJournal articlepeer-review

  3. Trans-ethnic gut microbial signatures of prediabetic subjects from India and Denmark

    Research output: Contribution to journalJournal articlepeer-review

  4. Trans-ethnic gut microbiota signatures of type 2 diabetes in Denmark and India

    Research output: Contribution to journalJournal articlepeer-review

  5. Whole blood co-expression modules associate with metabolic traits and type 2 diabetes: an IMI-DIRECT study

    Research output: Contribution to journalJournal articlepeer-review

  1. Common variants in breast cancer risk loci predispose to distinct tumor subtypes

    Research output: Contribution to journalJournal articlepeer-review

  2. Gene–gene interaction of AhRwith and within the Wntcascade affects susceptibility to lung cancer

    Research output: Contribution to journalJournal articlepeer-review

  3. I am hiQ—a novel pair of accuracy indices for imputed genotypes

    Research output: Contribution to journalJournal articlepeer-review

  4. Risk of ulcerative colitis and Crohn's disease in smokers lacks causal evidence

    Research output: Contribution to journalJournal articlepeer-review

  • Leila Dorling
  • Sara Carvalho
  • Jamie Allen
  • Michael T Parsons
  • Cristina Fortuno
  • Anna González-Neira
  • Stephan M Heijl
  • Muriel A Adank
  • Thomas U Ahearn
  • Irene L Andrulis
  • Päivi Auvinen
  • Heiko Becher
  • Matthias W Beckmann
  • Sabine Behrens
  • Marina Bermisheva
  • Natalia V Bogdanova
  • Stig E Bojesen
  • Manjeet K Bolla
  • Michael Bremer
  • Ignacio Briceno
  • Nicola J Camp
  • Archie Campbell
  • Jose E Castelao
  • Jenny Chang-Claude
  • Stephen J Chanock
  • Georgia Chenevix-Trench
  • J Margriet Collée
  • Kamila Czene
  • Joe Dennis
  • Thilo Dörk
  • Mikael Eriksson
  • D Gareth Evans
  • Peter A Fasching
  • Jonine Figueroa
  • Henrik Flyger
  • Marike Gabrielson
  • Manuela Gago-Dominguez
  • Montserrat García-Closas
  • Graham G Giles
  • Gord Glendon
  • Pascal Guénel
  • Melanie Gündert
  • Andreas Hadjisavvas
  • Eric Hahnen
  • Per Hall
  • Ute Hamann
  • Elaine F Harkness
  • Mikael Hartman
  • Frans B L Hogervorst
  • Antoinette Hollestelle
  • NBCS Collaborators
View graph of relations

BACKGROUND: Protein truncating variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2 are associated with increased breast cancer risk, but risks associated with missense variants in these genes are uncertain.

METHODS: We analyzed data on 59,639 breast cancer cases and 53,165 controls from studies participating in the Breast Cancer Association Consortium BRIDGES project. We sampled training (80%) and validation (20%) sets to analyze rare missense variants in ATM (1146 training variants), BRCA1 (644), BRCA2 (1425), CHEK2 (325), and PALB2 (472). We evaluated breast cancer risks according to five in silico prediction-of-deleteriousness algorithms, functional protein domain, and frequency, using logistic regression models and also mixture models in which a subset of variants was assumed to be risk-associated.

RESULTS: The most predictive in silico algorithms were Helix (BRCA1, BRCA2 and CHEK2) and CADD (ATM). Increased risks appeared restricted to functional protein domains for ATM (FAT and PIK domains) and BRCA1 (RING and BRCT domains). For ATM, BRCA1, and BRCA2, data were compatible with small subsets (approximately 7%, 2%, and 0.6%, respectively) of rare missense variants giving similar risk to those of protein truncating variants in the same gene. For CHEK2, data were more consistent with a large fraction (approximately 60%) of rare missense variants giving a lower risk (OR 1.75, 95% CI (1.47-2.08)) than CHEK2 protein truncating variants. There was little evidence for an association with risk for missense variants in PALB2. The best fitting models were well calibrated in the validation set.

CONCLUSIONS: These results will inform risk prediction models and the selection of candidate variants for functional assays and could contribute to the clinical reporting of gene panel testing for breast cancer susceptibility.

Original languageEnglish
Article number51
JournalGenome Medicine
Volume14
Issue number1
Pages (from-to)51
ISSN1756-994X
DOIs
Publication statusPublished - 18 May 2022

Bibliographical note

© 2022. The Author(s).

    Research areas

  • Breast Neoplasms/genetics, Case-Control Studies, Female, Genetic Predisposition to Disease, Humans, Mutation, Missense

ID: 78222632